[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2021167418A3 - Novel tumor-associated antigen protein olfm4 and uses thereof - Google Patents

Novel tumor-associated antigen protein olfm4 and uses thereof Download PDF

Info

Publication number
WO2021167418A3
WO2021167418A3 PCT/KR2021/002157 KR2021002157W WO2021167418A3 WO 2021167418 A3 WO2021167418 A3 WO 2021167418A3 KR 2021002157 W KR2021002157 W KR 2021002157W WO 2021167418 A3 WO2021167418 A3 WO 2021167418A3
Authority
WO
WIPO (PCT)
Prior art keywords
olfm4
associated antigen
tumor
antigen protein
novel tumor
Prior art date
Application number
PCT/KR2021/002157
Other languages
French (fr)
Korean (ko)
Other versions
WO2021167418A2 (en
Inventor
성승용
박현미
백범서
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Publication of WO2021167418A2 publication Critical patent/WO2021167418A2/en
Publication of WO2021167418A3 publication Critical patent/WO2021167418A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel tumor-associated antigen protein olfactomedin 4 (OLFM4) and to uses thereof. Specifically, it was confirmed that dendritic cells loaded with OLFM4 or an antennapedia peptide (ANTP)-conjugated OLFM4 recombinant protein induce a tumor-specific cytotoxic immune response, and thus, using the OLFM4 as a tumor-associated antigen protein, antigen-presenting cells loaded with the tumor-associated antigen protein or cytotoxic T lymphocytes derived from the antigen-presenting cells can be advantageously used for cancer immunotherapy.
PCT/KR2021/002157 2020-02-19 2021-02-19 Novel tumor-associated antigen protein olfm4 and uses thereof WO2021167418A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0020231 2020-02-19
KR1020200020231A KR102397922B1 (en) 2020-02-19 2020-02-19 Novel tumor-associated antigen protein OLFM4 and the use thereof

Publications (2)

Publication Number Publication Date
WO2021167418A2 WO2021167418A2 (en) 2021-08-26
WO2021167418A3 true WO2021167418A3 (en) 2021-10-14

Family

ID=77391596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/002157 WO2021167418A2 (en) 2020-02-19 2021-02-19 Novel tumor-associated antigen protein olfm4 and uses thereof

Country Status (2)

Country Link
KR (1) KR102397922B1 (en)
WO (1) WO2021167418A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077289A1 (en) * 2001-02-15 2003-04-24 Rong-Fu Wang Use of cell-penetrating peptides to generate antitumor immunity
KR101224466B1 (en) * 2010-05-20 2013-01-22 가톨릭대학교 산학협력단 Tumor antigen protein, gene, or peptides from topoisomerase 2 alpha
KR20180129899A (en) * 2016-03-31 2018-12-05 네온 테라퓨틱스, 인크. New antigens and how to use them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6559279B1 (en) * 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
KR100585456B1 (en) 2003-09-30 2006-06-07 국립암센터 Dendritic cell pulsing allogeneic tumor-associated antigen, method for the preparation thereof and vaccine composition containing same for treating cancer
KR100982186B1 (en) 2010-01-21 2010-09-14 전남대학교산학협력단 Novel tumor antigen protein agr2 and tumor antigenpeptide thereof
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US9381210B2 (en) * 2013-04-15 2016-07-05 Wisconsin Alumni Research Foundation Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077289A1 (en) * 2001-02-15 2003-04-24 Rong-Fu Wang Use of cell-penetrating peptides to generate antitumor immunity
KR101224466B1 (en) * 2010-05-20 2013-01-22 가톨릭대학교 산학협력단 Tumor antigen protein, gene, or peptides from topoisomerase 2 alpha
KR20180129899A (en) * 2016-03-31 2018-12-05 네온 테라퓨틱스, 인크. New antigens and how to use them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 6 July 2004 (2004-07-06), ANONYMOUS : "OLFM4 protein, partial [Homo sapiens] ", XP055855874, retrieved from NCBI Database accession no. AAH47740 *
YANG QIAN; BAVI PRASHANT; WANG JULIA Y.; ROEHRL MICHAEL H.: "Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 168, 29 June 2017 (2017-06-29), AMSTERDAM, NL , pages 53 - 65, XP085185171, ISSN: 1874-3919, DOI: 10.1016/j.jprot.2017.06.021 *

Also Published As

Publication number Publication date
KR102397922B1 (en) 2022-05-13
WO2021167418A2 (en) 2021-08-26
KR20210105587A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
ZA952375B (en) Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof
CL2020002387A1 (en) Peptides (seq id no: 39) and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer (application divisional no. 202002123)
EP3712165A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2001094413A3 (en) B7-related nucleic acids and polypeptides and their uses for immunomodulation
SI1922335T1 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
CA2409748A1 (en) Soluble ctla4 mutant molecules and uses thereof
WO2002099119A3 (en) B7-related nucleic acids and polypeptides useful for immunomodulation
WO2010022740A3 (en) Hiv-1 envelope polypeptides for hiv vaccine
PT1734049E (en) Tumour-associated peptides that bind to mhc-molecules
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO1998056919A3 (en) Methods and reagents for vaccination which generate a cd8 t cell immune response
CR20210129A (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MX2021009274A (en) Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide.
MX2021003420A (en) Tertiary amino lipidated cationic peptides for nucleic acid delivery.
CL2020002950A1 (en) Peptides and peptide combinations for use in immunotherapy against leukemia and other cancers (divisional application 201902878)
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
AU2003213580A1 (en) Subtilisin carlsberg proteins with reduced immunogenicity
SG126893A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2021167418A3 (en) Novel tumor-associated antigen protein olfm4 and uses thereof
CR20200607A (en) Immunotherapy against melanoma and other cancers
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
WO2003089451A3 (en) Antibodies specific for mucin polypeptide
EP2292638A3 (en) MAGE-C2 antigenic peptides and uses thereof
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
WO2005068632A8 (en) EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21757496

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21757496

Country of ref document: EP

Kind code of ref document: A2